吉林敖东(000623.SZ)：盐酸纳洛酮注射液获得药品补充申请批准通知书

Core Viewpoint - Jilin Aodong (000623.SZ) announced that its subsidiary, Yanji Pharmaceutical Group, received approval from the National Medical Products Administration for the "Naloxone Hydrochloride Injection" [1] Group 1: Product Approval - The approval is for Naloxone Hydrochloride Injection, which is an opioid receptor antagonist [1] - Indications for use include: 1. Reversal of respiratory depression caused by opioid drugs after combined anesthesia [1] 2. Complete or partial reversal of respiratory depression due to opioid overdose [1] 3. Rescue from acute ethanol poisoning [1] 4. Diagnosis of acute opioid overdose [1]